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Abstract
The development of capsule endoscopy (CE) in 2001 
has given gastroenterologists the opportunity to 
investigate the small bowel in a non-invasive way. CE is 
most commonly performed for obscure gastrointestinal 
bleeding, but other indications include diagnosis or 
follow-up of Crohn’s disease, suspicion of a small 
bowel tumor, diagnosis and surveillance of hereditary 
polyposis syndromes, Nonsteroidal anti-inflammatory 
drug-induced small bowel lesions and celiac disease. 
Almost fifteen years have passed since the release of 
the small bowel capsule. The purpose of this review 
is to offer the reader a brief but complete overview 
on small bowel CE anno 2014, including the technical 
and procedural aspects, the possible complications and 
the most important indications. We will end with some 
future perspectives of CE.
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Core tip: This review covers all the relevant aspects of 
small bowel capsule endoscopy anno 2014. The current 
techniques, procedures, analyses, indications and 
future perspectives are discussed thoroughly. Easy-to-
use flowcharts are provided to help the readers in their 
decision-making when confronted with small bowel 
pathology.
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INTRODUCTION
Wireless Video capsule endoscopy (CE) was invented by 
Gavriel Iddan[1] in the mid-1990s. Being able to visualize 
the entire small bowel in a noninvasive, well-tolerated way, 
CE has closed the diagnostic gap between conventional 
gastroduodenoscopy and colonoscopy. Since the official 
release of  CE in 2001, almost 15 years have passed, and 
CE has revolutionized the diagnosis and treatment of  
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various small intestinal diseases. This review aims to 
provide state of  the art on CE in gastrointestinal diseases. 
Both the evolution in technique and in indications will be 
discussed. 
TECHNICAL PRINCIPALS, PROCEDURE 
AND ANALYSIS
Capsule definition 
The wireless CE system consists of  4 main parts: (1) the 
single-use wireless Video Capsule; (2) sensor arrays or a 
sensor belt attached to the patient; (3) the data recorder 
attached to the belt; and (4) the computer workstation 
with the application software[2-4] as can be seen in Figure 
1 by Pan et al[4].
The capsule weighs less than 4 g and measures about 
11 mm in diameter × 26 mm in length. It is made of  
plastic, biocompatible and resistant to digestive fluids. 
The capsule contains a short focal lens and a miniature 
video camera: a charge-coupled device or Complementary 
Metal Oxide Semiconductor, which focuses the image. 
The gastrointestinal tract is illuminated by white light 
LEDs. The capsule is powered by two mercury free silver 
oxide batteries with a life span of  8-12 h. More than 
5000 images are transmitted during this battery life at a 
rate of  2-6 fps. Capsule features have evolved since the 
release of  the first capsule and nowadays standards are a 
156-170° field of  view, a high resolution and sharpness 
with a minimum size of  detection of  0.07 mm, a 1:8 
magnification, a more homogenous light exposure and a 
depth of  view of  at least 20-30 mm[5]. The captured data 
are sent to the sensor arrays and belt worn by the patients 
by either ultra-high frequency band radio telemetry or 
human body communications, using the human body as 
conductor. 
At present, there are three main companies supplying 
wireless CE systems by approval of  the FDA. Given 
Imaging (Ltd, Yoqneam, Israel) supplying the PillCam® 
SB 3, Olympus America (Inc, Center Valley, Pennsylvania) 
supplying the EndoCapsule® and Intromedic Company 
(Ltd, Seoul, South Korea) manufacturing the MiroCam®. 
Although not approved by the FDA, another Chinese 
company, Jianshan Science and Technology (Group) 
Co., Ltd., Chongqing, has developed its own capsule: 
the OMOM capsule. The capsule has been approved by 
the State Food and Drug Administration of  the People’s 
Republic of  China in March 2004 and is since then 
being used in China, Southeast Asia and some European 
countries[6]. The first large clinical trials have reported 
a yield and completion rate similar to the PillCam, 
but the major advantage of  the OMOM capsule is 
without doubt its price, which could be reduced by fifty 
percent[6,7] (Table 1 and Figure 2).
Even though the three main capsules approved by 
the FDA differ in technical specifications, several trials 
have shown that they offer a comparable diagnostic yield, 
image quality and completion rate, as was stated in the 
systematic review by Koulaouzidis et al[8].
Small bowel preparation 
To ensure a clear view on CE, the patient is asked to start 
fasting 12 h before the small bowel CE procedure[2,3]. 
However, due to bubbles, small intestinal fluid and biliary 
secretions coming from the major duodenal papilla, the 
visualization by the VCE can deteriorate. Furthermore, 
limited battery life span can hamper a complete intestinal 
examination in patients with delayed gastric emptying 
and small bowel transit, which necessitates the use of  
additional small bowel preparation[3]. However, not 
all patients are eligible for small bowel cleaning. The 
2012 Consensus guidelines for the safe prescription 
and administration of  oral bowel-cleansing agents[9] 
states that small bowel preparation is contraindicated in 
patients with gastrointestinal obstruction, perforation, 
ulceration, ileus, gastric retention or inflammatory 
bowel diseases (IBD), in patients with a reduced level 
of  consciousness, swallowing disorders, hypersensitivity 
to the used agent and in patients having an ileostomy. 
The use of  small bowel cleansing agents is relatively 
contraindicated in patients with chronic kidney disease 
or undergoing dialysis, in patients with a renal transplant, 
congestive heart failure, liver cirrhosis or ascites and 
in patients taking Renin-angiotensin blockers, diuretics 
or nonsteroidal anti-inflammatory drugs (NSAIDs). In 
these patients the utility of  small bowel cleaning should 
be reconsidered and the choice of  cleaning agent is of  
main importance: polyethylene glycol (PEG) is normally 
preferred over Sodium Phosphate. Patients taking Renin-
angiotensin blockers, diuretics or NSAIDs are advised 
to discontinue their medication temporarily and their 
hydration and electrolyte status should be checked prior 
to the small bowel preparation. In a recent systematic 
review, Kotwal et al[10] compared the results of  various 
randomized-controlled trials regarding improvement 
of  vision quality (VQ), diagnostic yield (DY) and 
completion rate (CR) by small bowel preparation. In this 
review, administration of  2L polyethylene glycol (PEG) 
the evening before VCE was found to be superior to 
two doses of  45 mL Sodium Phosphate before VCE 
regarding VQ and DY improvements. Another study by 
Kantianis et al[11] showed that 2 L as well as 4 L PEG did 
not differ in small bowel cleansing and CR. Therefore 
2 L should be preferred as regimen before VCE. 
Furthermore Kotwal et al[10] stated that simethicone, 
an antifoaming agent, significantly improved the VQ 
by decreasing the bubbles without implications on CR. 
Yet no significant improvement in VQ and DY were 
observed by combining Simethicone with PEG. After 
meta-analysis prokinetics did not show a significant 
improvement in CR, so they are not recommended.
Procedure
After bowel preparation, the patient gets eight sensor 
arrays attached to his body and a sensor belt fastened 
around his waist. The data recorder is attached to the 
belt before capsule ingestion. The capsule is ingested 
with a glass of  water and fluid restriction is needed till 2 
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h after ingestion. After 4 h, fasting can be stopped. Daily 
activities do not need to be interrupted during CE. 
Capsule propulsion needs to be followed by real-time 
viewing during the first hour to make sure the capsule 
passes the stomach. If  not, gastroscopy is performed to 
deposit the capsule in the duodenum.
The sensor arrays and belt are removed once the 
capsule has been expelled into the colon (as verified by 
real-time viewing), or when the battery life has expired. 
Images can be downloaded from the recorder to the 
workstation. The capsule itself  passes naturally with 
bowel movement and is usually excreted within 24 to 72 h.
Analysis
After downloading the data from the recorder to 
the workstation, images can be reviewed by gastro-
enterologists using the application software. Reading 
time and interpretation are around 40-120 min[2,12] which 
can be, compared to conventional endoscopy, a time-
consuming activity. A solution to this problem might 
be to train nonphysicians in pre reading the images. A 
study by Bossa et al[12] found that a nurse with expertise 
in endoscopy might be able to shorten the time needed 
by the endoscopist to read a capsule. Moreover the 
pre reading of  the CE by the nurse endoscopist led 
to a more careful approach of  the physician in the 
flagged areas, which enhanced the accuracy of  the CE 
investigation. Another recent study by Dokoutsidou et 
al[13] confirmed these findings and stated that despite 
a longer reading time, a nurse is perfectly capable of  
pre reading and subsequently flagging aberrant images. 
However, another possibility to lower reading time is 
the use of  special software to select aberrant images, 
which can be revised afterwards. With the introduction 
of  Quickview by Given Imaging, reading time could 
be reduced significantly. The Quickview software 
samples sites of  interest for review at a chosen rate, 
but unfortunately missed lesions occur far more often, 
which is unacceptable[14]. However, in certain clinical 
settings, such as overt obscure gastrointestinal bleeding 
(OGIB) in an urgent inpatient setting and suspected 
Crohn Disease or occult OGIB in outpatient setting, 
Koualouzidis et al[15] found that Quickview could be 
used confidently without clinical consequences. To 
enhance the yield of  CE, virtual chromoendoscopy 
was developed by adding colour filters to the images. 
Fuji Intelligent Colour Enhancement (FICE) was seen 
to be superior in detecting small bowel lesions and in 
particular angioectasias compared to conventional CE[16]. 
In another trial by Krystallis et al[17] Blue Mode (BM) was 
found superior to FICE in detecting lesions of  the small 
bowel. Adding BM to Quickview studies however did 
not show any diagnostic advantage and is therefore not 
recommended[15].
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Figure 1  Main parts of the wireless capsule endoscope.
1 Optical dome
2 LED
3 Short-focus lens
4 CMOS image sensor
5 RF model
6 MCU
7 Power model
Table 1  Comparison between commercially available capsule endoscopy devices
Capsule PillCam® SB 3 
Given Imaging
EndoCapsule® 
Olympus America
MiroCam®  
Intromedic Company
OMOM® 
Jianshan Science and Technology
Size Length: 26.2 mm
Diameter: 11.4 mm
Length: 26 mm 
Diameter: 11 mm
Length: 24.5 mm
Diameter: 10.8 mm
Length: 27.9 mm
Diameter: 13 mm
Weight 3.00 g 3.50 g 3.25-4.70 g 6.00 g
Battery life 8 h or longer 8 h or longer 11 h or longer 6-8 h or longer
Resolution 340 x 340
30% better than SB2
512 x 512 320 x 320 640 x 480
Frames per second 2 fps or 2-6 fps 2 fps 3 fps 2 fps
Field of view 156° 145° 170° 140°
Communication Radio Frequency 
Communication 
Radio Frequency 
Communication
Human Body 
Communication 
Radio Frequency 
Communication 
FDA approval Yes Yes Yes No
Price per capsule $500 $500 $500 $250
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Most of  the time, retained capsules are asymptomatic, 
but intestinal obstruction, partial or complete, may occur, 
especially in case of  known CD or neoplastic lesions. 
In the 2009 consensus by the European Society of  
Gastrointestinal Endoscopy it is recommended with a 
grade B evidence level to precede the CE by small bowel 
imaging or a patency capsule (PC) (cf. infra) in patients 
with suspected or established CD to rule out potential 
strictures. As said earlier, known small bowel obstruction 
is a contraindication for CE and patients at risk for a 
small bowel obstruction should therefore be carefully 
investigated by their physician before a CE procedure[24].
Evacuation of  the retained capsule can be spontaneously, 
medically or by surgery. The latter is unfortunately the 
most frequent intervention, but is on the other hand safe 
and can be seen as a required diagnostic and therapeutic 
tool for treating the underlying small bowel condition. 
With the surgery, not only the capsule is removed, but 
also the responsible lesion can be resected, which reliefs 
the patient’s symptoms. However retention can also lead 
to unnecessary surgery of  lesions caused by, e.g., NSAID 
or CD, for which a medical solution would also have 
been an option[25]. 
In recent years, an endoscopic approach of  capsule 
retention has become more popular as a less invasive 
alternative for surgery. Before capsule retrieval a 
radiographic localization of  the capsule is done to 
determine whether an upper or lower gastro-intestinal 
and a standard (gastroduodenoscopy, Push Enteroscopy 
or colonoscopy) or advanced endoscopic approach 
COMPLICATIONS AFTER CE
Capsule retention
Although very popular for its non-invasive character, 
CE can be the cause of  unnecessary treatment due to 
complications. One of  the most feared complications 
is capsule retention. It is defined as the presence of  
the capsule in the bowel lumen for a minimum of  2 
wk after ingestion, or when the capsule is retained for 
an unspecified period of  time unless targeted medical, 
endoscopic or surgical intervention is started[18]. 
According to a systematic review by Liao et al[19] 
overall retention rates are as low as 1.4%, which makes 
the procedure acceptable, regarding the high overall 
diagnostic yield of  59.4%. Furthermore, the retention 
rate differs according to the underlying pathology, with 
up to 2.6% in known Crohn’s disease (CD) and 2.1% 
in patients with Neoplastic Lesions[19]. This can be 
explained by the fact that capsule retention is usually 
caused by masses, strictures and stenotic areas resulting 
from neoplastic lesions, CD, NSAID consumption or 
post-operative adhesions, which narrow the small bowel 
lumen and favors retention[20]. In this regard, known 
small bowel obstruction, strictures and extensive CD are 
a contraindication for CE[21]. In a large study by Höög 
et al[22] risk factors for capsule retention were identified. 
OGIB and suspected CD were associated with the lowest 
chance of  capsule retention, whereas known CD and 
small bowel tumors had a higher chance of  retention. 
These findings were also confirmed by other authors[19,23]. 
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Figure 2  Types of small bowel capsule endoscopes. A: PillCam SB 3 (Given Imaging, Yoqneam, Israel); B: MiroCam (IntroMedic, Seoul, South Korea); C: Endo 
Capsule (Olympus America, Center Valley, PA); D: OMOM (Jinshan Science and Technology, Chongqing, China). 
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(device assisted enteroscopy) is needed. In this regard, 
surgery can be considered when endoscopic approaches 
did not manage to retrieve the capsule or when the 
patient presents with symptoms of  toxicity[26]. In a study 
by Van Weyenberg et al[27] DBE showed to be an adequate 
tool to retrieve a retained capsule. Moreover the DBE 
was capable to aid in pre-operative staging by histological 
sampling. In conclusion DBE can prevent unnecessary 
surgery as well as determine the cause of  the capsule 
retention before the operation, which is beneficial both 
for physician and patient.
Capsule perforation
Another yet very rare complication is perforation 
of  the small bowel. Usually it results from capsule 
retention. In the few cases that are reported, CD was 
the most frequent underlying pathology causing the 
perforation[20,28-31]. In a study by Repici et al[28] a possible 
explanation for this complication is given. CD affects the 
tissue of  the small bowel wall and makes it vulnerable. 
By the complete luminal occlusion due to the entrapment 
of  the capsule and the high peristaltic activity the fragile 
tissue of  the small bowel wall distends just above the 
capsule and leads to fissuration and possible perforation 
of  this area. One study by Gonzalez Carro et al[32] 
reported perforation after CE in a patient with a history 
of  surgery with subsequent adhesions. Because of  the 
major implications, perforation should be acknowledged 
as a possible complication after CE in patients with 
known or suspected CD.
Capsule interference
One of  the relative contra-indications for CE is the 
presence of  implantable cardiac devices, such as 
pacemakers, ICDs, pulsatile and nonpulsatile LVADs. 
Interference may arise during the CE procedure resulting 
in an alteration of  atrial or ventricular assistance[33]. This 
is however a theoretical assumption without clinical 
significance, because few studies show actual interference 
between cardiac devices and CE. Moreover, previous 
studies have already suggested that CE can be used safely 
in patients with these devices[34-41]. Only one study by 
Dubner et al[42] reported oversensing of  an ICD due to 
interference with the CE procedure, which resulted in 
an inappropriate shock by the cardiac device. In another 
case report by Guyomar et al[37] interference between 
pacemaker and video capsule occurred, resulting in a 
failure of  recording by the capsule when close to the 
pulse generator. Harris et al[43] found similar results in 
a 2013 study: all implantable devices proved to be safe 
for the patient, but LVAD had the tendency to interfere 
with image capture and therefore a CE lead position as 
far away from the LVAD as possible is required. On the 
other hand, in the article by Cuschieri et al[40] no loss of  
images was observed. In conclusion, close monitoring 
is recommended in patients with implantable cardiac 
devices but the risk for complications seems to be 
extremely low.
Capsule aspiration
Some cases have reported the existence of  bronchial 
aspiration of  the capsule. It is a very rare complication, 
which occurs in one out of  every 800 investigations 
and can be asymptomatic[44]. CE aspiration can resolve 
spontaneously[45], but often necessitates immediate 
radiological investigations to localize the capsule, 
followed by bronchoscopy to retrieve it with the aid 
of  a Roth Net[44]. To prevent this unnecessary invasive 
procedure, screening for patients at risk should be done. 
Risk factors include aging, neurological or swallowing 
disorders and patients with a weak or absent cough[46,47]. 
Direct placement of  the capsule in the gastrointestinal 
tract should be considered in these patients[44-46,48]. If  
not, the Real Time Viewer should be used during the 
ingestion of  the capsule to make sure that the capsule 
reaches the gastrointestinal tract[46-48]. 
Until now, only one fatality has been reported due 
to intracerebral haemorrhage resulting from capsule 
aspiration[47]. The reason for this low mortality rate 
is hypothesized in a study by Lucendo et al[44] stating 
that the size of  the capsule is not capable to block the 
total lumen of  the trachea and therefore still allows 
adequate oxygenation after capsule aspiration. However 
Koulaouzidis et al[49] found that the CE size might be 
correlated with the chance of  aspiration. 
ADDITIONAL FEATURES AND 
ENHANCEMENTS IN THE FIELD OF CE
Suspected blood indicator
In 2003 Given Imaging introduced the Suspected Blood 
Indicator (SBI) as an aid in diagnostics. The new feature 
highlights images suspected for redness or blood, which 
makes it easier for physicians to identify possible bleeding 
sites accurately. The software is activated when the 
capsule has reached the duodenum and operates only 
during its stay in the small bowel[50].
Sensitivity of  the SBI software is determined by the 
presence of  active bleeding. In studies, sensitivity ranges 
from 20% to 56.4% and increases up to 58.3% to 93% 
in case of  active bleeding[50-52]. However, sensitivity and 
specificity of  SBI remains too low, so complete review 
by a gastroenterologist is still required and the SBI 
only serves as rapid screening tool for actively bleeding 
lesions[51,52]. 
The detection rate of  the SBI is affected by back-
ground color of  the small bowel as by velocity of  the 
capsule[50]. This is also a possible explanation for the 
variation in sensitivity observed among different studies. 
The background of  the small bowel differs according 
to patient’s condition and small bowel preparation[50]. In 
experimental small intestine models, a very pale magenta 
background showed the highest detection rate, followed 
by burnt sierra and yellow. Lowest detection rates were 
observed in small bowel sites with colors significantly 
different from the normal small bowel color or when the 
capsule reached a high velocity. In an interesting study by 
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Buscaglia et al[53] SBI was found to be an inferior screening 
tool for sites of  potential bleeding with a sensitivity below 
60% even in active bleeding. Yet they found that in CD 
the SBI could be used as a screening tool for detection 
of  aberrant mucosa with high sensitivity. Another study 
by D’Halluin et al[54] also rejected the SBI software as 
a useful tool for screening the small bowel stating that 
the detection rate was poor, independent of  the type 
of  lesion. Furthermore they found that the SBI missed 
certain lesions while tagging few others and that irrelevant 
flagging might unnecessarily prolong the reading time of  
the CE. However, in a recent study Tal et al[55] stated that 
SBI is a reliable aid in excluding active bleeding or major 
lesions, but that the role of  the endoscopist could not be 
neglected. In summary we can conclude that SBI might 
improve the interpretation and thereby the yield of  CE 
by tagging areas for a second review, but can certainly not 
replace the gastroenterologist’s review. 
PC
To address the problem of  capsule retention, the Agile 
PC was developed by Given Imaging. The PC with the 
same size as a video capsule, serves as dummy to assess 
the patency of  the small bowel prior to CE examination. 
As one of  the major contraindications for CE is 
suspicion of  small bowel stenosis, routine administration 
of  PCs could enable safe CE use in a larger patient 
population by ruling out possible stenoses[56]. The PC 
system consists of  two main parts: the capsule itself  
with a radiofrequency identification tag (RFID tag) and 
an external detector system to capture radio-frequency 
signals. 
The PC is made of  lactose and 10% barium, which 
dissolves when coming into contact with intestinal fluids 
through the window at the edge of  the capsule, also 
known as timer plug. To insure that the timer plug is not 
blocked by capsule impaction in a stricture, the second 
generation PCs consist of  two timer plugs. If  excretion 
does not occur, dissolution starts at 30 h. After 35 h, 38 
percent of  the capsules are dissolved and all are dissolved 
within 72 h[57]. After dissolution, the remains of  the 
capsule encounter no difficulties to pass the small bowel 
strictures.
The detector system receives the radio-frequency 
signals coming from the RFID tag and reconstructs the 
exact capsule position. This can also be done by using 
radiography, which visualizes the PC by its radiopaque 
RFID tag or 10% barium[56]. Localization can be 
complicated by overlap of  intestines so subsequent 
fluoroscopy or CT scan can be warranted. One drawback 
of  the RFID tag system is the probability of  impaction 
in a stricture, which can lead to small bowel ileus[58]. 
Recently a new tag-less PC was developed by Given 
Imaging to overcome this issue and proved its usefulness 
as found by Nakamura et al[58].
The PC procedure is not as strict as the CE pro-
cedure. The capsule can be swallowed without previous 
food restrictions. If  the capsule is not excreted in 33 h, 
further examination is warranted to localize the PC and 
make a distinction between a small bowel and a colonic 
localization. The latter is still an indication for VCE. 
The subsequent CE has to be done quickly after PC so 
a possible change of  stricture status and subsequent 
capsule retention is avoided[56].
The use of  the PC still remains controversial. 
Although some authors have reported its utility[59-61], 
others have found that the capsule was not capable of  
confirming stenoses, which were found on CT or small 
bowel follow through[62]. In conclusion, patients still 
benefit from a CT investigation prior to CE to exclude 
possible stenosis and strictures.
CapsoCam capsule 
Over the last decade, a new player entered the field of  
CE. CapsoCam by Capsovision renewed the concept of  
CE by offering a capsule with a 360° view and on-board 
storage, which enables the retrieval of  images wire-free 
after interception of  the capsule in the feces. The capsule 
contains four cameras, which offer high resolution images 
and a frame rate up to 20 fps max. Furthermore, two 
new technologies were developed, Smart Motion Sense 
Technology and Auto Illumination Technology. Smart 
Motion Sense Technology enables the capsule to activate 
its cameras only during capsule motion. When the capsule 
is stationary, a sensor is used to compare the current 
frame with the previous frame to control reactivation. 
Auto Illumination Technology controls the 16 white 
LEDs to provide the optimal level of  illumination. 
When the capsule is located nearby the walls, a low light 
intensity is optimal to capture the best images. A position 
further away from the wall necessitates a higher light 
intensity. By adding these software features, battery life is 
sustained up to 15 h. The first clinical trial that used the 
CapsoCam accepted it as a safe and efficient tool in small 
bowel evaluation[63]. In a recent French study by Pioche 
et al[64] the concordance between the PillCam SB2 and 
CapsoCam was evaluated in terms of  diagnostic yield 
and image quality. A kappa value of  0.63 was obtained, 
which confirms the good concordance between the two 
capsules. Although the reading time of  the CapsoCam 
was longer, the CapsoCam detected significantly more 
lesions in a per lesion analysis.
Three-dimensional representation
In recent years, three-dimensional representation 
is becoming a hot issue. By reproducing the depth 
information lost by camera recording, diagnosis can be 
facilitated, because the texture and the abnormalities 
of  the mucosa are highlighted. 3-D rendering can be 
software- or hardware-based. The latter is limited by the 
technological possibilities of  the capsule, so software 
based 2-D to 3-D conversion is used[65,66]. Software-
based 3-D rendering uses algorithms to recreate the 
third dimension. In a study by Karargyris et al[67] four 
Shape-from-Shading (SfS) algorithms were compared. 
The Tsai’s SfS algorithm excelled the other algorithms in 
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visualization improvements, but we may not forget that 
the evaluation criterion was subjective in origin. However, 
the Tsai’s SfS algorithm is especially adapted to bright 
and round surfaces, therefore perfectly applicable in small 
bowel endoscopy.
Lesion localization
Apart from the image quality, accurate lesion localization 
is one of  the key elements of  CE, because further 
therapeutic steps, non-invasive and invasive, can 
depend on the exact localization of  the lesion[68]. Lesion 
localization is currently estimated according to the transit 
time and the use of  pylorus and caecum as landmarks, 
but lacks precision.
Exact localization can be determined by using a 
capsule emitting a magnetic field or electromagnetic 
waves. Both methods have their advantages and 
drawbacks. Magnetic-field-strength-based localization is 
not attenuated by the human body and the capsule does 
not have to be aligned with the detectors to be detected. 
As a drawback, interference of  the magnetic fields for 
capsule localization and the magnetic fields for active 
capsule movement in the future (cf. infra) may occur. On 
the other hand electromagnetic waves localization, such 
as the previously mentioned RFID tag, is based on radio-
frequency waves, which are attenuated by the human 
body and therefore may lose precision. A promising step 
forward in capsule localization is the development of  a 
new software by Olympus Medical Systems Corporation 
(Tokyo, Japan), which uses a 3D-triangulation. The exact 
capsule position is calculated by determining its distance 
from the 6 radiofrequency sensors using radiofrequency 
signal strength. In the study by Marya et al[69] an average 
localization error of  13.26 cm3 by attenuation was 
observed, especially in patients with an increased BMI. 
Finally, in 2010 the Capsule-odometer, a conceptual 
CE design, was proposed by Karargyris et al[70] which in 
theory offers a more accurate lesion localization. The 
capsule has two protruding wheels attached to a spring-
mechanism, so the wheels can adapt to the diameter 
of  the intestinal lumen, serving as a micro-odometer 
with subsequent accurate lesion localization, calculated 
from the onset of  the capsule investigation. This design 
also offered a greater stability, avoiding non-forward 
movement through the gastrointestinal tract. Further 
experiments and research are needed on this subject. 
MAJOR INDICATIONS FOR SMALL 
BOWEL CE
CE has been approved for various indications. These 
include (1) overt and occult obscure gastrointestinal 
bleeding; (2) suspected CD; (3) surveillance in patients 
with polyposis syndromes and detection of  small bowel 
tumors; (4) screening and evaluation of  NSAID side-
effects; and (5) suspected malabsorptive syndromes such 
as celiac disease. These indications will be explained 
further on in this paper. Relative contra-indications 
for CE include, like mentioned before: (1) known or 
suspected GI obstruction, strictures or fistulas; (2) cardiac 
devices; (3) swallowing disorders; and also (4) pregnancy.
Obscure gastrointestinal bleeding
Obscure gastro intestinal bleeding (OGIB) is defined 
as bleeding of  unknown origin that persists or recurs 
following a bidirectional negative endoscopic evaluation 
of  the gastrointestinal tract. OGIB is a common problem 
encountered by gastroenterologists, and accounts for 
approximately 5% of  all GI bleedings[71]. OGIB can be 
overt (melena, hematochezia, hematemesis) or occult 
(iron-deficiency anaemia, IDA, with or without a positive 
fecal occult blood test). OGIB is mostly caused by a 
lesion located in the small bowel, but can also originate 
from a lesion in the other parts of  the GI tract as 
well, missed with conventional endoscopy because 
of  intermittent bleeding or by human error[72]. The 
underlying pathology is age dependent. Under the age of  
40, the most frequently detected lesion is a small bowel 
tumor, followed by Meckel’s diverticulum, Dieulafoy’s 
lesion and CD. Above the age of  40, vascular lesions such 
as angiodysplasia are most frequently observed, counting 
for up to 40% of  the underlying lesions. NSAID-induced 
lesions (cf. infra) are the second most frequent finding on 
CE[71]. 
Since its development in 2000, CE has mainly 
been used for the indication of  OGIB, accounting for 
60%-70% of  the patients[8]. CE has proven superiority 
to all other diagnostic modalities in OGIB, such as 
barium contrast radiology, small bowel computed 
tomography (CT), magnetic resonance imaging (MRI), 
push enteroscopy and angiography, as can be seen in 
Table 2. The American Society for Gastrointestinal 
Endoscopy (ASGE) confirmed these findings in their 
guidelines presented in 2007[71]. Before using CE as a 
diagnostic tool, at least one gastroduodenoscopy and 
ileocolonoscopy have to be performed to rule out upper 
and lower gastrointestinal tract abnormalities. Repeating 
gastroscopies or colonoscopies immediately prior to CE 
in patients who have not had endoscopic investigations 
for more than 6 mo, tends to have a low diagnostic 
yield and is not cost-effective[73]. Therefore, CE is 
recommended as the first-line investigation after negative 
bidirectional endoscopies. Younger patients however 
have a higher chance of  IBD or tumours and a CT 
abdomen is indicated prior to CE to rule out stenosis[20]. 
A gynaecological etiology has to be considered in young 
females.
The overall yield of  CE is between 35% and 83% 
for OGIB[19,71,72,74-80] with its mean around 60%[81,82]. 
Diagnostic yield is influenced by the type of  bleeding. 
Patients with ongoing overt bleeding usually present 
with a higher diagnostic yield than patients with obscure-
occult bleeding, presenting as IDA[72,83]. More factors 
associated with a higher diagnostic yield have been 
identified, including low hemoglobin measurements, 
transfusion need, older age and a short interval of  less 
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Table 2  Comparison of different diagnostic modalities in obscure gastrointestinal bleeding
than 3 d between admission and the CE procedure[84-88]. 
CE is recommended in all cases of  OGIB because of  its 
diagnostic value and its impact on further management. 
A study by Albert et al[75] found that CE was able to 
determine the therapy in 66% of  the cases and led to an 
alteration in management in 32.3% of  the cases. This 
is in line of  previous studies, which reported that CE 
could alter subsequent management in 23%-66% of  the 
cases[79,85,89-91]. Sidhu et al[84] found that this management 
alteration could be predicted by patient comorbidity or 
angiodysplasia findings on CE.
The reason why CE has been recommended as first-
line examination tool over DBE after initial negative 
upper and lower endoscopies is its noninvasive nature and 
ease of  use, which makes it well-tolerated and feasible in 
an outpatient setting[92]. Furthermore its ability to visualize 
the whole small bowel in more than 80%-85% of  the 
cases[93,94] and the ability to determine the initial DBE 
approach makes it a helpful tool in OGIB diagnostics[92,95]. 
However, CE often fails to visualize lesions in the 
proximal small bowel, in a Roux-en-y loop and in patients 
presenting with diverticula[76]. 
If  necessary, a CE procedure can be followed by a 
double balloon enteroscopy (DBE) procedure[72]. DBE is 
the only diagnostic tool showing a similar diagnostic yield 
for OGIB as VCE, as can be seen in Table 2. However, 
the DBE procedure is more invasive, can be time-
consuming, requires training, needs sedation or general 
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Ref. Country Design No. of 
patients
Comparator Yield 
of CE, 
(%)
Yield of 
Comparator, 
(%)
Significant 
difference? 
(yes/no)
CE 
superior? 
(yes/no)
Other
Triester et al[80] United States Meta-analysis 
and Systematic 
review
396 PE 63 28 Yes Yes NNT = 3 to yield one 
additional clinically significant 
finding with CE
  88 SB radiography 
(barium contrast 
and enteroclysis)
67 8 Yes Yes NNT = 3 to yield one 
additional clinically significant 
finding with CE
Leighton et al[82] United States Meta-analysis 
and Systematic 
review
396 PE 63 28 Yes Yes Yield of significant findings: 
CE = 56% vs PE = 26%, NNT 
= 3 to yield one additional 
clinically significant finding 
with CE 
  88 Barium 
radiography
67 8 Yes Yes Yield of significant findings: 
CE = 42% vs SB barium 
radiography = 6%, NNT = 3 to 
yield one additional clinically 
significant finding with CE 
  42 Intraoperative 
enteroscopy
83 83 No No
  17 Mesenteric 
angiography
47 53 No No
Chen et al[205] China Meta-analysis 
and Systematic 
review
277 DBE 61 56 No No CE was superior if no 
combination of oral + anal 
approach <-> DBE was 
superior when a combination 
of the two insertion 
approaches was done
Pasha et al[95] United States Meta-analysis 
and Systematic 
review
397 DBE 24 24 No No CE should be the initial 
diagnostic test for determining 
insertion route of DBE
Arakawa et al[76] Japan Retrospective 
Study
162 DBE 54 64 No No
Teshima et al[77] Canada, The 
Netherlands
Meta-analysis 
and Systematic 
review
651 DBE 62 56 No Yes Yield of DBE after positive 
CE = 75.0% <-> yield after 
negative CE = 27.5%
Leung et al[206] China RCT   60 Mesenteric 
angiography
53 20 Yes Yes No significant difference 
in the long-term 
outcomes (transfusion 
need, hospitalization for 
rebleeding,mortality)
Wang et al[207] China Meta-analysis 
and Systematic 
review
279 CT 53 34 Yes Yes Complementary role to CE 
and can be used as a triage 
tool prior to DBE in evaluating 
OGIB 
PE: Push enteroscopy; CE: Capsule endoscopy; SB: Small bowel; NNT: Number needed to treat; DBE: Double balloon enteroscopy; RCT: Randomized 
controlled trial. 
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anesthesia and can have a complication rate of  up to 4.3% 
in therapeutic procedures as was reported by Mensink et 
al[96]. Moreover DBE is not always able to visualize the 
whole small bowel. A completion rate of  only 62.5% was 
achieved in DBE, compared to 90.6% in CE as reported 
by Nakamura et al[94]. Yet, DBE is preferred over CE in 
patients requiring a biopsy or a therapeutic intervention 
such as argon plasma coagulation (APC). Also DBE 
tends to have an acceptable yield in patients with an initial 
negative CE and suspicion of  a small bowel lesion[95,97], 
although it has been reported being much lower than the 
yield of  DBE following a positive CE, respectively 28% 
and 75%[77].
Not only clinically, but also economically is CE 
recommended as first line investigation of  OGIB. It 
has shown to be more cost-effective than DBE when 
only visualization of  the small bowel is needed[98]. 
Negative CE investigations usually do not require further 
diagnostic work-up, which saves money in the long term, 
because reimbursement for CE is less than for DBE[93]. 
A mean cost-saving of  €1738.07 was reported by Marmo 
et al[99] when CE was preferred over other modalities 
in OGIB and turned out to be positive. However, only 
reimbursement costs were evaluated, so the cost of  the 
hospital and the personnel was not taken into account.
If  a therapeutic intervention is needed with a 
probability of  more than 25%, gastroenterologists should 
consider the use of  DBE as initial therapeutic option 
to minimize costs[93]. Furthermore, cost equalization 
of  DBE and CE was reached at 100 procedures for 
diagnostic DBE and 79 procedures for therapeutic DBE, 
which suggests that DBE is especially cost-effective in 
large-scale hospitals, with a substantial number of  DBE 
procedures per year. Another study by Gerson et al[100] 
found that, regardless of  the cost, DBE procedure was 
more cost-effective than CE-guided DBE procedure, 
because no additional costs were charged regarding 
further examinations and therapy could be given instantly. 
However, the workload for physicians would significantly 
increase if  an initial DBE would be done and we may 
not forget that DBE is correlated with a higher rate of  
complications compared to CE. CE-guided DBE was 
associated with better outcomes in the long term because 
of  fewer potential complications and fewer utilization 
of  endoscopic resources. This can be explained by the 
high negative predictive value of  CE, which leads to a 
reduction in the subsequent DBE procedures[92,100]. 
When CE is negative, the chance of  rebleeding is low, 
so that further investigations can be deferred, even when 
a second test might be diagnostic[101-103]. Rebleeding was 
reported to be higher in CE-positive patients and patients 
using anticoagulants[103]. Nonetheless, gastroenterologists 
should consider close monitoring, alternative modalities 
in suspicious cases because the chance of  rebleeding has 
been reported up to 28.4% and 35.3% during a median 
follow-up of  respectively 23.7 mo and 31.7 mo[104,105]. 
Repeating the CE procedure however should only be 
considered if  the bleeding presentation switches from 
occult to overt bleeding or the hemoglobin level drops 
with more than 4 g/dL[106]. Diagnostic yield of  a repeated 
CE was reported to be between 35% and 75% and a 
subsequent management change was reported in 39% to 
62.5% of  the patients[107,108]. 
To conclude this chapter about OGIB, we have made 
a flow-chart to represent the current knowledge in this 
field. For this purpose we included the reviewed articles 
in previous flow charts[18,109] (Figure 3).
CD
Non-stricturing CD is the second main indication for CE. 
CD is a type of  chronic IBD which may affect the whole 
gastrointestinal tract and lead to mucosal and transmural 
damage. Categorization of  patients with CD is done 
based on the disease presentation: solely the small bowel 
(30%-35% of  the patients), the small bowel and the large 
bowel (45%-50%) or only the large bowel (20%)[110]. So 
even though it primarily affects the terminal ileum, the 
ileocecal region and the large bowel, one third of  the 
patients presents with only small bowel inflammation 
which challenges gastroenterologists to diagnose the 
disease. Traditionally small bowel involvement was 
diagnosed by radiological procedures, small bowel 
barium radiography, CT, colonoscopy with ileoscopy 
or enteroscopy. But with the invention of  CE, new 
possibilities in CD diagnostics have become available.
CE can be very helpful in the diagnosis of  new cases 
of  Crohn and in the evaluation of  known CD, with 
regard to the activity and extent of  the disease. CE is 
reserved however for cases with unexplained symptoms, 
when other investigations remain inconclusive or when 
CE would affect the management of  the patient[111]. 
So both in suspected as established CD, CE usually 
is performed third after a negative colonoscopy and 
ileoscopy, thereby replacing the traditional modalities. 
CE is considered positive for CD when more than 3 
ulcerations are identified in the absence of  NSAID 
use[111-113] or when 4 or more obvious clear ulcers, erosions, 
or a region with clear exudate and mucosal hyperemia 
and edema are seen[114].
Like in OGIB, CE also has shown a superior yield 
for detecting early inflammatory lesions in the small 
bowel comparing to all other modalities as can be seen 
in Table 3. The yield of  CE in non-stricturing CD has 
been reported to be between 18% and 96%[81,95,115-119]. 
Triester et al[81] only found a significant difference in 
yield between CE and other modalities for diagnosing 
non-stricturing small bowel CD. However, a distinction 
should be made between suspected and established 
CD. The reported superior yield was only significant 
for evaluating established CD and was not reported for 
diagnosis of  small bowel CD in patients with a suspected 
initial presentation of  the disease. This was contradicted 
by Dionisio et al[115], who found that CE has a superior 
yield compared to small bowel radiography (SBR), CT 
enterography (CTE) and colonoscopy with ileoscopy in 
the diagnosis of  suspected CD patients. Although the 
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yield of  CE in CD is high, the proportion of  CD patients 
diagnosed with CE is rather low (0%-4%). Only in young 
patients presenting with abdominal pain plus diarrhea 
a 30% chance of  diagnosing CD was achieved[114]. In 
established CD patients, CE was reported to be superior 
compared to SBR, CTE and PE, which was the same 
according to previous findings[115]. When compared 
to CT enterography and MR enterography, CE shows 
superior yields in the first two-thirds of  the small bowel, 
but loses this superiority in the last portion of  the small 
bowel by showing a yield similar to the comparators[120,121]. 
However, we may not forget that MR enterography is 
also capable of  visualizing the small bowel surroundings, 
so that transmural and extra-intestinal manifestations 
can be diagnosed[122]. A recent study by Leighton et al[123] 
found that a combination of  colonoscopy with ileoscopy 
and CE achieved a far more high yield than patients 
investigated with a combination of  colonoscopy with 
ileoscopy and small-bowel follow-through (SBFT). They 
confirmed the role of  CE as valuable third diagnostic 
option in diagnosis of  suspected CD, when colonoscopy 
and ileoscopy turned out to be negative or inconclusive.
In patients with suspected CD, Girelli et al[119] found 
that, presuming a pre-test probability of  CD of  50%, a 
positive CE was capable to raise the post-test probability 
up to 85% and if  the CE was negative, it was capable 
to lower the probability to only 5%. In patients with 
established CD, the use of  small bowel CE in monitoring 
therapy response is still a controversial issue. Many 
reports found that the clinical and biological response to 
treatment is not correlated with mucosal healing, which 
is monitored on CE, so it has not proven useful in this 
respect[124]. 
Caution should be taken when evaluating CEs positive 
for small bowel lesions. Because of  the potential of  CE 
to detect early lesions, CD-induced lesions are often 
non-specific and can be confused with NSAID-induced 
lesions. Both CD and NSAID-induced small bowel injury 
show endoscopically similar lesions and because of  the 
inability of  CE to take biopsies, the differential diagnosis 
remains inconclusive. Pathognomonic however for 
NSAID-induced lesions are the concentric diaphragmatic 
strictures in the ileum seen on endoscopy, which can lead 
to small bowel obstruction[125]. According to Doherty 
et al[126] the problem of  false positive capsules also 
overestimates the incremental yield of  CE compared 
to other modalities, necessitating a diagnostic golden 
standard to overcome the problem of  premature CD 
diagnoses. Currently, there are two scores available to 
assess and monitor mucosal disease activity on CE. The 
CE CD Activity Index (CECDAI or Niv score) and the 
Lewis score are only recently developed and still have 
to prove their usefulness in standardizing the diagnosis 
of  CD on CE before being widely accepted in clinical 
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Consider repeating gastroscopy or colonoscopy if the last investigation was less than 6 mo ago
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Figure 3  Recommended approaches for diagnosis and treatment of obscure gastrointestinal bleeding. 1DBE is recommended in (1) patients requiring a 
biopsy or a therapeutic intervention (2) patients with an initial negative CE and suspicion of a small bowel lesion (3) large scale hospitals or (4) hospitals where CE is 
not available; 2If a lesion is suspected, further work-up is needed; 3Rebleeding was defined as a change from occult to overt bleeding or a hemoglobin level drop more 
than 4 g/dL. DBE: Double balloon enteroscopy; PE: Push enteroscopy; IOE: Intraoperative enteroscopy; Routine endoscopy: Uni/bidirectional endoscopy.
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practice as an objective tool of  mucosal inflammation 
measurement[127,128]. Although the yield of  CE has been 
questioned by these diagnostic problems, CE still remains 
a valuable tool in the diagnosis of  CD: a recent study by 
Hall et al[129] found a very high negative predictive value 
in the long term despite the questioned yield in patients 
with suspected CD, which makes it capable of  safely 
ruling out suspected CD.
As mentioned before, capsule retention is especially 
feared in patients with CD because of  possible strictures 
and stenosis. The reported 2.6% by Sharaf  et al[130] has 
made small bowel imaging a standard exam previous to 
the CE procedure[19]. MR is a useful tool to asses patency 
of  the small bowel[131]. Another possibility is the use of  
the previously discussed Pillcam PC (Given Imaging, 
Yoqneam, Israel), which indicates patency if  the capsule 
is excreted intact or the scan has lost the RFID tag signal 
30 h after ingestion[132], so the CE procedure can be done 
to evaluate the mucosal surface of  the small bowel.
Cost analyses for CE in CD have been made and 
showed that colonoscopy with ileoscopy followed by 
a CT enterography was the most cost-effective choice 
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Table 3  Comparison of different diagnostic modalities in Crohn’s disease
Ref. Country Design No. of 
patients
Comparator Yield 
of CE, 
(%)
Yield of 
Comparator, 
(%)
Significant 
difference? 
(yes/no)
CE 
superior? 
(yes/no)
Other
Marmo et al[117] Italy RCT   31 SB radiography 
(enteroclysis)
71 26 Yes Yes Terminal ileum: 
yield 89% vs 37%
Proximal SB: yield 
only 46% vs 13%
Chong et al[208] Australia Blinded 
prospective 
trial
  43 SB enteroclysis
PE
77
77
19
14
Yes
Yes
Yes
Yes
Results are in 
patients with a 
history of CD
Triester et al[81] United States Meta-analysis 
and Systematic 
review
250 SB barium radiography 63 23 Yes Yes NNT = 3 to yield 
one additional 
diagnosis with CE
114 Colonoscopy with 
ileoscopy
61 46 Yes Yes NNT = 7 to yield 
one additional 
diagnosis with CE
  93 CT enterography/CT 
enteroclysis
69 30 Yes Yes
  84 PE 46 8 Yes Yes
  18 MR enterography 72 50 No Yes
Solem et al[118] United States Blinded 
prospective 
trial
  41 CT enterography
Colonoscopy with 
ileoscopy
Small bowel follow-
through
83
83
83
83
74
65
No
No
No
No
Yes
Yes
Specificity of 
CE (53%) was 
significantly 
lower than the 
other tests
Pasha et al[95] United States Meta-analysis 
and Systematic 
review
343 DBE 18 16 No No
Dionisio et al[115] United States Meta-analysis 
and Systematic 
review
428 SB barium radiography 52 16 Yes Yes
236 Colonoscopy with 
ileoscopy
47 (71)1 25 (36) Yes Yes Suspected CD 
(Established CD)
119 CT enterography 68 (71) 21 (39) Yes Yes Suspected CD
(Established CD)
102 PE 66   9 Yes Yes Established CD
123 MR enterography 55 (70) 45 (79) No Yes (no) Suspected CD 
(Established CD)
Lu et al[116] China Retrospective 
Study
  50 Colonoscopy with 
ileoscopy
96 66 Yes Yes Combination 
of two methods 
showed a higher 
yield, but no 
significant 
differences 
were reported 
between each two 
examinations
  34 CT enterography 96 85 Yes Yes
  39 Small bowel follow-
through
96 67 Yes Yes
1Extra information between brackets is specific for Established Crohn’s disease. PE: Push enteroscopy; CE: Capsule endoscopy; SB: Small bowel; NNT: 
Number needed to treat; DBE: Double balloon enteroscopy; RCT: Randomized controlled trial.
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among the different diagnostic options in patients 
suspected of  CD[133]. Moreover, CE was proven to be 
not cost-effective as third diagnostic option, because of  
the high false positive rate, the diagnostic yield and the 
low pre-test probability of  CD. Sharaf  et al[130] confirmed 
these findings and concluded that CE is not a valuable 
option in patients with suspected CD. However, Leighton 
et al[134] found that CE did play a significant role in early 
diagnostics of  CD, because it did not necessitate repeated 
procedures, physician visits and hospital stays, so direct 
costs could be reduced. Further investigation on this 
matter is needed.
In summary, CE has a superior diagnostic yield when 
compared to other modalities in suspected as well as 
established small intestinal CD. However, the question if  
this superior yield is due to false positive results remains 
unanswered. With the development of  two scoring 
systems, this problem might be solved in the near future. 
Still, CE is a promising tool in CD diagnostics because 
of  its capability to early diagnose small bowel lesions. 
We conclude with a flow chart based on the ICCE 
flowchart[131] and Mergener et al[109] with incorporation of  
new evidence[124,129] (Figure 4).
Surveillance of polyposis syndromes and detection of 
small bowel tumors
Small bowel tumors make up only 3%-6% of  the 
gastrointestinal neoplasm cases despite the 90% of  the 
gastrointestinal tract surface the small bowel covers, 
which makes it a difficult entity to diagnose[135,136]. The 
most frequently observed tumors are adenocarcinoma, 
gastrointestinal stromal tumor, carcinoid, lymphoma 
and sarcoma[137-140]. Symptoms are rather unspecific and 
include anaemia or overt OGIB and later abdominal 
pain, nausea, vomiting, weight loss and anorexia[141,142]. 
Thereby tumors are mostly found on CE or DBE when 
investigating patients with OGIB[80,139,140,143]. A study by 
Sîngeap et al[137] reported a detection rate for small bowel 
tumors of  4.9% in patients presenting with OGIB or 
other nonspecific symptoms. Other studies have found 
a tumor detection rate of  6%-12% on CEs done for 
OGIB[144]. The insidious process often is responsible 
for the delayed diagnosis of  a patient, which impacts 
the further management of  the patient[145]. Fast tumor 
detection is therefore very important, since management 
can be changed accordingly and outcomes can be 
improved even in malignant lesions if  metastasis is 
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Symptoms suspicious for small bowel Crohn’s disease
Noninvasive markers for small bowel inflammation (CRP and fecal proteins)1
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Figure 4  Recommended approaches for diagnosis and treatment of Crohn’s disease. 1Non-invasive markers have proven to be useful in giving baseline 
information about the presence of small bowel inflammation; 2If capsule endoscopy (CE) is negative, Crohn’s disease can be ruled out due to the high negative 
predictive value of CE. In that case, other explanations should be considered. CRP: C reactive protein.
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absent[146]. Small bowel tumors can be benign, potentially 
malignant, malignant or metastatic. However the 
majority, 60%, of  these tumors are malignant[144], and 
differentiation between benignant and malignant cannot 
be made on CE. Tumors mostly appear as masses or 
polyps, but also can present as ulcers and stenoses in a 
minority of  the cases. Hereditary polyposis syndromes 
like Familial Adenomatous Polyposis (FAP) and Peutz-
Jeghers Syndrome (PJS), are another entity and apart 
from the colon polyposis, patients often develop 
benignant small bowel pathology with a high tendency to 
evolve into cancer[147].
CE was evaluated for small bowel tumors and 
hereditary polyposis syndromes and turned out to be 
a valuable diagnostic tool[148,149]. The pooled detection 
rate of  CE was 55.9%[19]. Therefore, In patients with 
suspected small bowel tumors, CE can be the first choice 
in diagnostics[137]. In a study by Schulmann et al[147] it was 
stated that CE was capable of  detecting small bowel 
polyposis, located in the distal jejunum and ileum beyond 
the reach of  PE. These polyps could subsequently be 
removed by DBE, so surgery was avoided. However, 
most FAP patients with distal polyposis also presented 
with proximal polyposis, which was equally detected 
by CE as well as PE. Proximal jejunal polyposis is 
significantly correlated with the presence and severity of  
duodenal disease, which is one of  the main locations for 
adenocarcinoma and subsequent mortality. Because CE 
was capable of  detecting proximal small bowel polyposis 
and given its superior sensitivity and non-invasive nature, 
it was recommended as a surveillance tool in a subgroup 
of  FAP patients with severe duodenal polyposis[147]. 
Duodenal polyposis itself  is difficult to detect by CE, 
due to the rapid transit of  the capsule in this part of  
the gastrointestinal tract. Another study by Plum et al[150] 
confirmed the superiority of  CE compared to other 
modalities such as PE, ileoscopy and enteroclysis in 
patients with FAP. However, they also stressed on the fact 
that CE did not replace the other modalities, because CE 
sometimes missed lesions and did not manage to precisely 
localize the small bowel lesions. Also a study by Wong 
et al[151] confirmed the fact that CE could underestimate 
the number of  small bowel polyps in FAP and a review 
by Koornstra[152] stated that CE cannot totally replace 
standard endoscopy in the surveillance of  the proximal 
small bowel. A tool to overcome missed lesions might 
be the recently developed CICE tool, which enhances 
the contrast of  the CE images and thereby improves the 
visibility in patients with small bowel polyposis. Although 
further evaluation is needed, a first trial showed that half  
of  the adenomatous polyps could be better visualized 
and hamartomatous polyposis was better visible[153].
In PJS, CE was capable of  detecting lesions with 
direct impact on further management. CE is the most 
accurate diagnostic tool to detect small bowel polyposis 
throughout the whole small bowel and can be seen as 
a safe alternative for the traditional modalities, such 
as PE and MR enteroclysis used in PJS and FAP[147]. 
The superiority of  CE over MR enterography was 
also confirmed by Liao et al[19] who found that CE was 
capable of  detecting smaller small bowel lesions. Urgesi 
et al[143] stated that CE could detect more lesions than the 
traditional endoscopy and radiological imaging in patients 
suspected for small bowel tumors. They concluded that 
CE played an important role in the diagnostic work-up 
of  these patients[143]. Similarly another very recent study 
by Urquhart et al[154] found that CE was able to identify 
significantly more small bowel polyps compared with 
MRE in patients with PJS. Furthermore, Rahmi et al[155] 
found that CE was also useful in planning the DBE 
approach in patients in need of  polypectomy. DBE, 
which achieves a similar yield as CE, is useful when 
biopsy, exact pre-operative localization or local therapy, 
such as stenting or balloon dilatation is needed[156].
CE also has its limitations in the detection of  small 
bowel tumors. First of  all it is not useful in an emergency 
setting, such as obstruction and peritonitis, because of  
the risk of  capsule retention[145]. Furthermore, CE is not 
capable of  treating locally or taking biopsies, needed to 
differentiate between benignant and malignant[157]. Finally 
CE is not able to differentiate a mucosal bulge from a 
smooth-walled tumor. To overcome the latter problem, 
the scoring system SPICE (Smooth, Protruding lesion 
Index on CE) has been developed. A score greater than 
2 is suggestive of  small bowel malignancy, but further 
validation is needed[158]. 
Just like in CD, the risk of  capsule retention is 
present. Yet the rate is lower in patients with intestinal 
tumors compared to patients with CD[19]. Moreover, 
Bailey et al[146] stated that obstructions due to neoplasms 
were a positive complication because, since the tumor 
anyway needed to be treated by enteroscopy or surgery, 
the impacted capsule could serve as a guide. Like in 
CD, if  the patient is suspicious for obstruction, imaging 
should be done before CE. Management of  malignant 
small bowel tumors is primarily surgical. In selected 
cases, this can be performed laparoscopically. Adjuvant 
chemotherapy and radiotherapy may be needed, 
depending on the histology of  the tumor[135].
We can conclude by stating that CE is a diagnostic 
tool with a big value regarding its yield in diagnosis and 
surveillance of  small bowel tumors/polyps. However, it is 
complementary to the traditional modalities and can not 
substitute them. CE is recommended third after negative 
bidirectional endoscopy in patients with OGIB or other 
unspecific symptoms indicating a possible small bowel 
tumor. It can be used first as a complementary diagnostic 
tool in patients with established hereditary polyposis 
syndromes. We summarized the evidence in two flow-
charts based on the Consensus statements for small−
bowel CE, 2006/2007 by Mergener et al[109] and a study by 
Plum et al[150] (Figures 5 and 6).
NSAID side-effects
NSAIDs can inflict injury along the whole gastrointestinal 
tract, when used for a prolonged time. Although many 
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publications have emphasized on the incidence of  upper 
gastrointestinal lesions, fewer have mentioned lower 
gastrointestinal ones. However, as mentioned before, 
NSAIDs can also induce small bowel lesions, which can 
be observed on CE. In fact, these lesions are far more 
common than the NSAID-induced gastropathy[159]. 
Furthermore, complications in the lower gastrointestinal 
tract, such as perforation, bleeding, or obstruction are 
currently increasing while upper GI complications are 
decreasing[160], which necessitates the need of  small bowel 
diagnostics in the field of  NSAID side-effects.
In seventy percent of  the patients using NSAIDs 
continuously, mucosal damage of  the small intestine has 
been reported on CE or DBE[161,162]. Even a two-week 
NSAID-regimen with slow-release diclofenac resulted 
already in macroscopic injury of  the small intestine in 
68%-75% of  the volunteers[163]. Different types of  lesions 
have been observed ranging from mucosal redness 
and multiple petechiae to erosions, ulcers, loss of  villi, 
diaphragm-like strictures, which are pathognomonic 
for NSAID-induced enteropathy, and even severe 
bleeding[164,165]. Most symptomatic patients present with 
OGIB with or without obstruction symptoms and are 
accordingly diagnosed[166,167]. 
Both CE and DBE have been evaluated for NSAID-
induced lesions. They show a similar yield of  60% in 
diagnosis[166,168]. CE however is preferred for screening 
of  NSAID-induced lesions and evaluation of  further 
treatment because of  its non-invasive character. DBE on 
the other hand is the first choice in patients suspicious 
of  strictures. NSAID-use has been recognized as a risk 
factor for capsule retention and CE should therefore 
be avoided in these patients[19]. Furthermore DBE 
is preferred when further examination of  the lesion, 
endoscopic or histologically, is needed or when local 
therapy has to be given, such as balloon dilatation of  a 
stricture or endoscopic coagulation, clipping or injection 
of  the bleeding site. Balloon dilatation of  a stricture 
seems to be safe, since the muscularis propria remains 
intact and perforation is subsequently rarely observed[156]. 
A recent study by Tacheci et al[169] confirmed the high 
sensitivity of  CE and further stated that subclinical 
small bowel damage also could be observed on CE. If  
NSAID enteropathy is found on CE or DBE, further 
investigation can be done using other modalities such 
as radiological examination, the permeability test, 
scintigraphy, the fecal excretion with 111In white blood 
cells and measurement of  the calprotectin concentration 
in the feces[164].
Just like in CD, scoring systems are available to 
classify lesions and to consider and evaluate further 
treatment[127,161,163,168]. However, no standard scoring 
system is thoroughly evaluated. Different therapeutic 
options are available. The first choice of  therapy is a 
discontinuation in the use of  NSAIDs, which in most 
cases is not possible due to the underlying pathology[161]. 
Cyclooxygenase-2 (COX-2) selective inhibitors, 
prostaglandin derivatives, a combination of  NSAIDs and 
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Symptoms suspicious for small bowel tumors: OGIB, diarrhea, abdominal pain,…
Bidirectional endoscopy Specific treatmentPositive
Positive
Negative
Negative
Capsule endoscopy
Consider other explanations
Low probability
CT or MR enterography
Normal imaging Abnormal imaging
Insignificant clinical historySignificant clinical history
Diagnostic DBE or PE Repeat capsule endoscopy
Mass on capsule endoscopy
Intermediate/high probability
CT or MR enterography to assess 
extraluminal disease
DBE or PE polypectomy
Adjuvant chemotherapy or radiotherapy
Surgery
Figure 5  Recommended approaches for diagnosis and treatment of small bowel tumors. DBE: Double balloon enteroscopy; PE: Push enteroscopy; OGIB: 
Obscure gastrointestinal bleeding.
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phosphatidylcholine, cytoprotective drugs and probiotics 
are all useful for the treatment of  NSAID-induced small 
intestinal injuries[159]. Yet controversy remains around 
the use of  selective COX-2 agents. A trial by Goldstein 
et al [170] reported that a 2-wk regimen of  selective 
COX-2 agents caused fewer small intestine injuries than 
treatment with a nonspecific NSAID. This was confirmed 
in a big RCT by Chan et al[171]. However, Maiden et al[172] 
showed that COX-2 selective inhibitors caused the same 
amount of  small bowel damage as long-term NSAIDs, 
which is interesting given the fact that they affect the 
gastroduodenal mucosa to a lesser extent[170]. So COX-2 
might play a significant role in the maintenance of  the 
small bowel integrity. We can conclude that it remains 
unclear whether selective COX-2 inhibitors truly prevent 
NSAID-induced enteropathy.
Also chronic Low-dose aspirin (LDA) users are at 
risk of  small bowel enteropathy. The phenomenon was 
first described by Leung et al[171] in 2007 and the study by 
Endo et al[165] was the first to report the characteristics of  
the small bowel damage associated with long-term LDA 
use. The use of  LDA however was less harmful than 
other types of  NSAIDs[166]. These findings may have 
implications on treatment of  the large group of  patients 
requiring anti-inflammatory or antithrombotic drugs.
Celiac disease
Celiac disease is caused by an chronic auto-immune 
response of  the intestines to gliadins in the diet and 
occurs in approximately 1% of  the population in 
genetically susceptible persons[174]. It is characterized by 
duodenal folds, scalloping of  folds, mucosal fissures, 
crevices or grooves, visible submucosal vessels, mi-
cronodules in the duodenal bulb and a mosaic pattern 
in the small bowel mucosa[175]. The lesions are visible on 
CE, which makes CE therefore a perfect tool to assess 
small bowel damage in these patients. In a large meta-
analysis by Rokkas et al[176] sensitivity and specificity 
of  CE in celiac disease have been reported up to 89% 
and 95% respectively. This was similar to a previous 
meta-analysis by El-Matary et al[177] which reported a 
sensitivity of  83% and a specificity of  98%. However, to 
confirm celiac disease in patients with positive serologic 
markers, a biopsy is needed, which is not possible with 
the current capsules. Therefore, the gold standard for 
the diagnosis of  celiac disease remains the histological 
findings of  a small bowel specimen obtained through 
gastroduodenoscopy. 
The main indications to use CE are serological 
positive patients, who are unwilling to undergo gas-
troduodenoscopy or patients with antibody-negative 
villous atrophy. The latter group showed a higher 
yield on CE, compared with CE in serological positive 
patients with biopsy-proven celiac disease and persisting 
symptoms as was found by Kurien et al[178]. Also in 
patients with non-responsive celiac disease, defined by 
persistent or recurrent symptoms under treatment with 
a gluten-free diet, CE showed to be of  use to detect 
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Patients suspected of polyposis syndromes
Bidirectional endoscopy
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Patients with  polyposis syndromes, suspected of small bowel involvement
CT or MR enterography
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Figure 6  Recommended approaches or diagnosis of small bowel hereditary polyposis. DBE: Double balloon enteroscopy; PE: Push enteroscopy. 
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complications, such as multiple erosions, ulcerations, 
ulcerative jejunitis and adenocarcinoma[179]. Tennyson 
et al[180] confirmed these findings, but emphasized that 
CE was not a necessary tool in the evaluation of  non-
responsive celiac disease when no alarm symptoms are 
present, such as weight loss and abdominal pain, or when 
no loss of  T-cell antigens on intraepithelial lymphocytes 
or loss of  clonality of  the T-cell receptor gene was 
observed. In the latter situations, a combination of  CE 
and CT or MR enterography should be performed. 
In all other cases, upper gastroduodenoscopy with 
biopsy remains the gold standard. A recent study by 
Van Weyenberg et al[181] found similar results stating 
that CE could be used in patients with non-responsive 
celiac disease to identify the cases who are at risk of  
complications. CE might also be useful in the follow-
up of  patients with celiac disease under treatment with a 
gluten-free diet, regarding mucosal healing, because the 
follow-up of  duodenal histology is not representative for 
the mucosal healing more distally[182]. Finally, Akin et al[183] 
confirmed other authors by stating that CE was useful 
as an alternative to duodenal biopsy in patients unable or 
unwilling to undergo gastroduodenoscopy and further 
stated that CE could be of  use in the diagnosis of  celiac 
disease in elderly patients with unspecific symptoms.
In conclusion, gastroduodenoscopy remains the 
diagnostic tool of  choice for celiac disease, but CE shows 
to be a useful adjunctive tool in specific situations. 
UPCOMING CHALLENGES
To conclude this paper about the current knowledge of  
CE, we would like to offer an insight in its bright future. 
Since its release in 2001, optics, battery life, visualization 
and software have been improved, with consequences on 
yield, completion rate and reading time. We have already 
discussed some technological advances in CE, but we 
will now shortly focus on future expectations of  this 
technology. 
One major field of  advancement will be the ma-
neuverability. If  a capsule endoscope would be steerable 
and could approach a site of  interest, this could be 
a big step forward in the diagnosis and treatment of  
diseases of  the whole gastrointestinal tract. With efficient 
movement, battery life could sustain during movement 
through the whole gastrointestinal tract and thereby 
could increase completion rate. Various studies have 
been done and many prototype active capsules, using 
different locomotion techniques are currently under 
investigation for human use[184-188]. However, in the near 
future, remote manipulation using magnetic forces will 
be the first to be commercially available. These capsules 
contain a magnet, which can then be mobilized with an 
externally handled magnetic paddle or with a joystick. 
Perspective of  the camera also can be adjusted with this 
magnet, rendering the desired image[189]. Swain et al[190] 
was the first to document the use of  a magnetic field 
to guide a capsule through the human oesophagus and 
stomach. Since this article, many studies have followed, 
especially focusing on investigation of  the stomach[191-194]. 
To overcome the problem of  capsule impaction and to 
improve mucosal visualization, especially in the colon, 
insufflation techniques have recently been described by 
several authors using a capsule with a magnetic controlled 
drug release system to create a basic chemical reaction 
forming CO2 in the lumen[195-197]. Another very interesting 
topic is a novel wireless platform able to measure and 
locate the force opposing capsule motion as a reflection 
of  the gastrointestinal tract resistance[198]. It is the first 
platform for magnetic control of  CEs that implemented 
this intermagnetic force measurement feature.
Another advancement might be the availability 
of  a controlled drug release feature. This could help 
gastroenterologists in the local treatment of  various 
gastrointestinal diseases, such as medical treatment 
of  CD or even hemostasis in OGIB. Only one study 
introduced a capsule able to microposition a needle and 
to deliver 1 mL of  a targeted medication, while resisting 
peristalsis with its holding mechanism[199]. 
The inability of  taking biopsies is a third challenge 
CE faces. Together with an accurate maneuverability, this 
could enable CE to completely take the place of  DBE 
in diagnostic and even therapeutic endoscopy of  the 
small bowel. In 2008, Valdastri et al[200] was the first to 
successfully report an in vivo experiment with a capsule 
with built-in clip-releasing mechanism. The VECTOR 
project by the European Commission is currently 
developing a capsule for diagnosis and treatment of  
gastrointestinal cancer[201]. Another study also investigated 
the use of  a large number of  thermo-sensitive 
microgrippers in CE for this purpose of  grabbing and 
retrieving tissue samples, which showed promising 
results[202].
Finally, to end this paper, we would like to reflect on 
the environmental consequences of  capsule endoscopies, 
a subject that will become more important in the future, 
given the growing importance of  CE. Although the 
ASGE consensus states that the capsule is “disposable 
and designed to be excreted”[3], considerations around 
this topic should be made, since the capsule contains 
many particles with potential biohazards[203]. Pezzoli 
et al[204] was the first to publish a small article on this 
matter in 2011. They found that it was possible, after 
retrieval and cleaning, to reactivate used capsules with a 
10 min procedure and a new battery cost of  only 2 euro. 
Recycled capsules could then be given a second life in, e.g., 
veterinary procedures[205].
CONCLUSION
This paper gives a brief  but complete overview on small 
bowel CE anno 2014. As the technology is still evolving 
and new insights are still being published every year, we 
emphasize that healthcare-providers should continue to 
monitor the medical literature for recent data, in order to 
provide the best evidence-based care for their patients. 
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